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Mucopolysaccharidosis type II (MPSII), or Hunter syndrome, arises from a deﬁciency in iduronate 2-sulfatase (IDS), and it is characterized
by progressive somatic and neurological involvement. The MPSII mouse model reproduces the features of MPSII patients. Systemic
administration of the AAV2/5CMV-hIDS vector in MPSII mouse pups results in the full correction of glycosaminoglycan (GAG) accumu-
lation in visceral organs and in the rescue of the defects and GAG accumulation in the central nervous system (CNS). Remarkably, in
treatedMPSII animals, this CNS correction arises from the crossing of the blood-brain barrier by the IDS enzyme itself, not from the brain
transduction. Thus, we show here that early treatment of MPSII mice with one systemic injection of AAV2/5CMV-hIDS results in pro-
longed and high levels of circulating IDS that can efﬁciently and simultaneously rescue both visceral and CNS defects for up to 18
months after therapy.Iduronate-2-sulfatase (IDS) is the enzyme that removes the
sulfate group from dermatan and heparan sulfate, and its
inactivity results in MPSII (MIM 309900), or Hunter
syndrome, a rare X-linked inborn error of metabolism.
The incidence of MPSII has been estimated at around 1
in 162,000 live births. The deﬁciency of IDS has been
shown to be due to point mutations or deletions in the
24 kb IDS gene.1 As with all of the human sulfatases, IDS
needs to be activated by sulfatase modifying factor 1
(SUMF1)2,3 (MIM 607939).
MPSII occurs in both severe and mild forms that cover
a broad spectrum of symptoms with slow to rapid patho-
logical progression. The severe form is characterized by
progressive somatic and neurological involvement, with
an onset between the second and fourth years of age and
an early mortality. Facial features, hepatosplenomegaly,
short stature, skeletal deformities, joint stiffness, severe
retinal degeneration, and hearing impairment are coupled
to an incremental deterioration of the neurological
system.4
The MPSII (idsy/) mouse model displays the features of
Hunter syndrome.5 Affected mice develop skeleton defor-
mities, particularly of the craniofacial bones, as well as
alopecia, and they showed irregular gait, an abnormal
walking pattern, and poor locomotor and exploratory abil-
ities in the open-ﬁeld test. IDS activity is not detectable in
any of their tissues, and the affected animals show a
progressive accumulation of glycosaminoglycans (GAGs)
in many organs and in their urine. In addition, MPSII
mice present neuropathological defects. The onset of the
gross morphological phenotype is manifested at 3–4
months of age, it becomes progressively severe through
their adult life, and MPSII mice usually die by about 60
weeks of age.6 We have previously used an AAV type 2/8
vector carrying human IDS cDNA under the control of
the thyroxine-binding globulin liver-speciﬁc promoter296 The American Journal of Human Genetics 85, 296–301, August 1(AAV2/8TBG-hIDS) to engineer liver secretion of IDS.
This efﬁciently corrected the visceral organs through IDS
uptake from the blood.6 It is now imperative to develop
an efﬁcient therapy to treat the CNS symptoms. Ideally,
having circulating IDS that crosses the blood-brain barrier
(BBB) would be highly preferred and would provide treat-
ment of both visceral and CNS defects, simultaneously.
The BBB is formed by a layer of endothelial cells of the
brain microvasculature that regulates the passage of mole-
cules between the blood and the CNS. Tight junctions
block the passage of most molecules, except some speciﬁc
substances that cross the BBB via receptor-mediated trans-
port.7
Enzyme-replacement therapy at high doses in mouse
models of a-mannosidosis (MIM 609458), MPSVII (MIM
253220), and metachromatic leukodystrophy (MIM
250100) leads to enzyme delivery across the BBB, thereby
partially reversing storage in brain tissues.8–10 Similarly,
the intrahepatic administration of AAV2 vectors in MPSVII
mice results in some correction of the CNS phenotype.11
We have previously shown that systemic administration
of AAV2/8TBG-hIDS can lead to very high levels of circu-
lating IDS, which partially cleared glycosaminoglycan
(GAG) accumulation in the choroid plexus of idsy/ mice.6
To anticipate disease manifestation and to simulta-
neously treat the visceral and CNS defects of MPSII, we
have again systemically administered the AAV type 2/5
vector carrying human IDS cDNA, but here under the
control of the cytomegalovirus promoter (AAV2/5CMV-
hIDS), in day 2 (p2) idsy/ mouse pups. We used this type
of vector because it has been shown to provide efﬁcient
transduction of several tissues, such as skeletal muscle
and lung.12,13 We observe full correction of the CNS symp-
toms and visceral defects. Furthermore, we provide
evidence that correction of CNS storage and neuronal
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Groups of p2 idsy/ pups were injected in the temporal
vein with 1 x 1011 AAV2/5CMV-hIDS viral particles, and
the treated mice were sacriﬁced in two groups: after 1
month (T1; n ¼ 8) or 18 months (T18; n ¼ 4) of therapy.
Control wild-type (WT) (n ¼ 5) and MPSII (n ¼ 5) mice
were analyzed in parallel. The IDS activities were analyzed
in the plasma of the mice at T1, T6, T12, and T18, and on
average, they were up to 5-fold higher in the treated mice
in comparison to the WT mice and up to 60-fold higher
in the treated mice in comparison to the idsy/ control
mice (Table 1). The untreated idsy/ mice died at 14
months. In contrast, the life span of the treated animals
was prolonged up to and beyond 18 months. To monitor
the systemic excretion of GAGs, we analyzed their accu-
mulation in the urine of the mice at T1, T6, T12, and
T18. GAGs were cleared in the urine of all of the treated
mice for up to 18 months after the therapy, and their accu-
mulation was almost fully normalized, as compared to WT
levels (Table S1, available online). AAV vector preparation,
plasma and urine collection, IDS activity assay, and quan-
titative analysis of GAG excretion were performed as previ-
ously described.6
Next, we tested IDS activity in homogenized tissues from
all of the control and treated mice. In the treated mice,
there was a remarkable rescue of IDS activity that reached
levels comparable to or higher than the IDS activities
measured in theWT tissues; this was seen for all of the eval-
uated tissues from the treated mice that were sacriﬁced at
T1 and T18 (Figure 1A). Surprisingly, a moderate rescue
of IDS activity was evident in brain homogenates of T1
Table 1. IDS Activity in the Plasma
IDS Activity (nmol/4 h/mg)
T1 T6 T12 T18
WT 320 5 27 2435 32.1 220 5 36.2 198 5 18.9
Idsy/ 27 5 1.5 24 5 0.6 18 5 1.1
Idsy/þIDS 2400
Idsy/þIDS 2700
Idsy/þIDS 1995
Idsy/þIDS 2090
Idsy/þIDS 2405
Idsy/þIDS 2820
Idsy/þIDS 1900
Idsy/þIDS 2340
Idsy/þIDS 2300 1410 909 820
Idsy/þIDS 1900 950 659 420
Idsy/þIDS 2435 1680 1409 1219
Idsy/þIDS 2230 1735 1380 1022
IDS activity in the plasma measured at different times after therapy (T1, T6,
T12, and T18: 1, 6, 12, and 18 months after the injection, respectively) of
WT (n ¼ 3), Idsy/ (n ¼ 3), and AAV2/5CMV-hIDS-injected Idsy/ mice.The Ameriand T18 mice (Figure 1B). This led us to predict that we
were measuring IDS activity of the enzyme that had
crossed the BBB. Indeed, much higher IDS activity would
be expected if there had been transduction of AAV2/
5CMV-hIDS in the brain.
GAG accumulation was fully cleared in the visceral
tissues of both of these treated groups (T1 and T18)
(Figure S1) and, remarkably, also in all of the brain areas
analyzed: the choroid plexus in the IV and III ventricles,
as well as the meninges, brainstem, cortex, hippocampus,
and thalamus (Figure 1C and Figure S2). This clearly
showed that even if we succeeded in only a partial rescue
of the IDS activity in the brain with this therapy, this
constant low level of IDS that had crossed the BBB was
sufﬁcient to totally clear the GAG CNS storage. Alcian
blue staining was performed as previously described.6
Then, to investigate this crossing of the BBB by IDS, we
analyzed human IDS expression in cDNAs from T1 and
T18 tissues. No positive expression signals were detected
in the brain samples of the control (WT and idsy/) or
treated (T1 and T18) mice. In contrast, there was clear
ampliﬁcation of IDS expression in the liver and lungs of
both treated groups. For controls, we also ampliﬁed
mouse Ids transcripts (Figure 2A and Figure S3). For
further conﬁrmation of these results, p2 WT mice were in-
jected with 1 x 1011 AAV2/5CMV-LacZ viral particles. LacZ
expression and b-galactosidase activity were seen only in
the liver and lungs, not in the brain (Figure 2B and data
not shown). This indicates that both of the hIDS and
LacZ transgenes from the AAV2/5 vectors were not ex-
pressed in the brains of the injected mice and that,
thus, the measured IDS activity was due to IDS uptake
from the bloodstream and its crossing of the BBB. Simi-
larly, by using real-time PCR, we could not detect any
AAV2/5 viral genomic DNA in the brains of the treated
mice, only in their livers, further ruling out crossing of
the BBB by AAV2/5 and transduction of the brains
(Figure 2C). By contrast, efﬁcient crossing of the BBB
was achieved by intravenous injections of the AAV9
vector.14 Reverse transcriptase-polymerase chain reaction
(RT-PCR) experiments were performed through ampli-
fying the cDNAs prepared from the brains, livers, and
lungs of WT mice, Idsy/ mice, and T1 and T18 AAV2/
5CMV-hIDS-injected Idsy/ mice (Superscript III Reverse
Transcriptase Kits; Invitrogen).
The progressive accumulation of GAGs in lysosomes of
neurons leads to severe vacuolization. This was cleared in
neurons of the brainstem, cortex, hippocampus, and thal-
amus of treated mice (Figure S4). Interestingly, diffuse neu-
rodegeneration in the thalamus, cerebral cortex, and
brainstem of untreated animals was clearly seen, through
observation of reduced neuronal density (decreased anti-
NeuN signal) and increased ubiquitin-expressing neurons,
as compared to theWT brain areas. This was also associated
with the triggering of apoptosis, as shown by TUNEL-
positive signals in neurons of the thalamus, cerebral
cortex, and brainstem of MPSII mice (Figure 3A and Figurescan Journal of Human Genetics 85, 296–301, August 14, 2009 297
Figure 1. Increase in IDS Activity and Rescue of GAG Accumulation in Idsy/ Mice after Temporal Vein AAV2/5CMV-hIDS Injection
(A) P2 Idsy/mice sacriﬁced 1 (T1) and 18 (T18) months after therapy. IDS activities in the treatedmice weremeasured in protein extracts
of: WT (n ¼ 5), Idsy/ (n ¼ 5), T1 Idsy/þIDS (n ¼ 8), and T18 Idsy/þIDS (n ¼ 4) mice.
(B) IDS measured in brain homogenates of the same groups of control and treatedmice. Error bars indicate standard deviations. p < 0.05
(Student’s t test).
(C) Alcian Blue-stained sections for GAG accumulation in different regions of brains of T14 Idsy/ control mice and T18 AAV2/5CMV-
hIDS-injected Idsy/ mice. Magniﬁcation: 203.298 The American Journal of Human Genetics 85, 296–301, August 14, 2009
Figure 2. IDS Protein Crossing of the BBB in AAV2/5CMV-hIDS -Injected Idsy/ Mice
(A) RT-PCR of IDS from brains, livers, and lungs of T18WT, T14 Idsy/, and T18 Idsy/þIDS mice, for ampliﬁcation of human and mouse
IDS mRNA.
(B)WTmice injected at p2 in the temporal vein with AAV2/5CMV-LacZ and sacriﬁced after 1month. RT-PCR of LacZmRNA from brains,
livers, and lungs of T1 WT and T1 WTþLacZ mice.
(C) Real-time PCR for ampliﬁcation of viral genomic DNA in brains and livers of T1 nontreated Idsy/mice (n ¼ 4) and T1 AAV2/5CMV-
hIDS-injected Idsy/ mice (n ¼ 4). Error bars indicate standard deviations. p < 0.05 (Student’s t test). The primers used were: forward
primer BGH: 50-TCTAGTTGCCAGCCATCTGTTGT-30, reverse primer BGH: 50-TGGGAGTGGCACCTTCCA-30, and the TaqMan probe
50-6FAM-TCCCCCGTGCCTTCCTTGACC-TAMRA-30 (LightCycler 480 Probes Master Kit, Roche). As standard, the diluted gene transfer
vector was used (from 13 107 copies to 1 copy per reaction). To obtain the vector copy number for each cell, we divided the values by the
number of cells corresponding to 100 ng of genomic mouse DNA.S5 and S6). In addition, in the white matter, there were
a-synuclein aggregates (Figure 3B), which have previously
been shown to accumulate in neurons during neurodegen-
erative disorders, such as Parkinson disease (MIM 168600)
and Alzheimer disease (MIM 104300), and also during
lysosomal storage disorders, such as Sandhoff disease
(MIM 268800), Tay-Sachs disease (MIM 272800), meta-
chromatic leukodystrophy, and beta-galactosialidosis15
(MIM 256540). Finally, in the treated mice, there were
also increased numbers of activated microglia (GFAP im-The Amermunohistochemistry) and massive inﬁltration of activated
macrophages (CD68 positivity) (Figure 3A and Figures S5
and S6).
Remarkably, in the T18 AAV2/5CMV-hIDS-injected
Idsy/ mice, there was clear amelioration or complete
correction of neurodegeneration (normalized staining of
NeuN, ubiquitin, TUNEL, and a-synuclein), astrogliosis
(normalized GFAP staining), and inﬂammation (normal-
ized CD68 staining) (Figures 3A and 3B and Figures S5
and S6). Furthermore, in one-month-old MPSII mice, weican Journal of Human Genetics 85, 296–301, August 14, 2009 299
observed increases in ubiquitin-expressing neurons and
astroglysosis in the thalamus, including an increase in
a-synuclein aggregates as well; these markers were
normalized in the group of T1 AAV2/5CMV-hIDS-injected
Idsy/ mice (Figures S7A and S7B). All of these data
demonstrate that with this therapy, we can prevent the
development of the CNS defects, along with the somatic
manifestations. Indeed, normalized horizontal and
vertical activities in the open-ﬁeld test measured in T18
AAV2/5CMV-hIDS-injected Idsy/ mice conﬁrmed their
Ids
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Figure 3. Rescue of Brain Defects in
AAV2/5CMV-hIDS-Injected Idsy/ Mice
(A and B) Immunohistochemistry of
different brain-speciﬁc markers (mono-
clonal anti-NeuN, diluted 1:100, Chemi-
con International; polyclonal anti-ubiqui-
tin, diluted 1:50, Abcam; TUNEL,
Chemicon International Staining Kit;
monoclonal anti-GFAP, diluted 1:200,
Sigma-Aldrich; and monoclonal anti-
CD68, diluted 1:250, AbD Serotec) in the
thalamus and white matter (monoclonal
anti-a-synuclein, diluted 1:250, Abcam) of
brain sections in T18 WT, T14 Idsy/, and
T18 AAV2/5CMV-hIDS-injected Idsy/
mice. Magniﬁcation: 103 (anti-NeuN
sections); 403 (anti-CD68 sections); or
203 (all others).
improved gross motor phenotype
(Figures S8A and S8B). The open-ﬁeld
test was performed as previously
described.6
All in all, this report clearly demon-
strates that with only one intravenous
systemic injection of AAV2/5CMV-
hIDS vector particles administered to
newborn p2 idsy/ mice, the mice do
not develop the systemic and CNS
disease phenotypes up to 18 months
of age. We have clearly shown that
the vector was not transduced in the
brains of the treated animals and
that the correction of the CNS symp-
toms was due to the crossing of the
BBB by IDS. Although at present we
do not know how IDS crosses the
BBB, the long half-life of circulating
IDS, as shown by its slow clearance
from the blood (high plasma levels
in treated animals), probably allows
the enzyme to cross the BBB. Interest-
ingly, chemically modiﬁed b-glucu-
ronidase showed slower plasma clear-
ance, and the modiﬁed enzyme
efﬁciently crossed the BBB after its
systemic infusion in MPSVII mice.16
Whether high circulating levels of
IDS are required for its delivery through receptor-mediated
uptake or via different routes, such as pinocytosis or trans-
cytosis, remains an open question.
MPSII patients affected by the severe form of the disease
ideally need to be treated with one administration of
the vector that can rescue both visceral and CNS defects.
In conclusion, with these ﬁndings, we believe to have
demonstrated that high circulating levels of the IDS
enzyme, coupled with very early treatment of the mice,
provide an effective therapy for MPSII in all of the affected300 The American Journal of Human Genetics 85, 296–301, August 14, 2009
tissues. Potentially, modulation of the physical parameters
of the enzymes, such as their stability, and early vector
administration might be useful approaches for the treat-
ment of other lysosomal-storage disorders.
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